目的 分析肾衰宁胶囊联合氢氯噻嗪片治疗慢性肾功能衰竭的临床效果。方法 选择2018年1月-2019年10月在鞍山市中心医院立山院区治疗的慢性肾功能衰竭患者60例，随机分为对照组（30例）和治疗组（30例）。对照组患者口服氢氯噻嗪片，2片/次，2次/d，隔日治疗。治疗组在对照组基础上口服肾衰宁胶囊，4粒/次，3次/d。两组患者均治疗8周。观察两组患者临床疗效，同时比较治疗前后两组患者临床症状改善时间，及尿素氮（BUN）、血肌酐（Scr）、内生肌酐清除率（Ccr）、白细胞介素-1β（IL-1β）、可溶性细胞黏附因子-1（sICAM-1）和肿瘤坏死因子-α（TNF-α）水平。结果 治疗后，对照组临床有效率为73.33%，显著低于治疗组的93.33%，两组比较差异有统计学意义（P<0.05）。治疗后，两组患者BUN和Scr水平均显著降低（P<0.05），而Ccr显著升高（P<0.05），且治疗组患者BUN、Scr和Ccr水平明显好于对照组（P<0.05）。治疗后，两组患者IL-1β、sICAM-1和TNF-α水平均显著降低（P<0.05），且治疗组患者IL-1β、sICAM-1和TNF-α水平明显低于对照组（P<0.05）。治疗后，治疗组患者食欲缺乏、浮肿、恶心和乏力等临床症状改善时间明显早于对照组（P<0.05）。结论 肾衰宁胶囊联合氢氯噻嗪片治疗慢性肾功能衰竭，可明显改善患者临床症状、肾功能、机体炎症状况，且安全可靠。

Objective To analyze the clinical effect of Shenshuaining Capsules combined with hydrochlorothiazide in treatment of chronic renal failure. Methods Patients (60 cases) with chronic renal failure in Anshan Central Hospital Lishan District from January 2018 to October 2019 were randomly divided into control (30 cases) and treatment (30 cases) groups. Patients in the control group were po administered with Hydrochlorothiazide Tablets every two days, 2 tablets/time, twice daily. Patients in the treatment group were po administered with Shenshuaining Capsules on the basis of the control group, 4 grains/time, three times daily. Patients in two groups were treated for 8 weeks. After treatment, the clinical efficacy was evaluated, and the improvement time of clinical symptoms, and the BUN, Scr, Ccr, IL-1β sICAM-1 and TNF-α levels in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control group was 73.33%, which was significantly lower than 93.33% in the treatment group, and there were differences between two groups (P<0.05). After treatment, the BUN and Scr levels in two groups were significantly decreased (P<0.05), but Ccr level was significantly increased (P<0.05), and the renal function in the treatment group was significantly better than those in the control group (P<0.05). After treatment, the IL-1β, sICAM-1, and TNF-α levels in two groups were significantly decreased (P<0.05), and which in the treatment group were significantly lower than that in the control group (P<0.05). After treatment, the improvement time of lack of appetite, edema, nausea and fatigue in the treatment group were significantly earlier than that in the control group (P<0.05). Conclusion Shenshuaining Capsules combined with hydrochlorothiazide in treatment of chronic renal failure can obviously improve the clinical symptoms, the renal function and the inflammatory, and which is safe and reliable.